Cel PL920055, a grant obtained for Biomed I, provided support for coordination of the concerted action (300,000ECUs over 3 years). The present proposal allows participation in this programme of centres from Eastern European Countries. Coronary atheroma is invisaged as a build-up over many years of layers of organized thrombus. This offers the possiblity of final control of the disease through control of the final common mechanism. Such control is predicted to be much more efficient and cost-effective than attempts to control the multiple primary factors individually. The final manifestations of the process, i.e.the acute coronary syndromes, are known to be thrombotic in nature and to be controllable through anti-thrombotic medication and will be studied by angioscopy (Rotterdam) and other techniques applicable during coronary angiography (Rotterdam and Brussels). The stenosed coronary artery with endothelial damage will be used as an animal model in which the efficacy of anti-thrombotic action will be tested (London, Dublin). Homocysteinaemia provides a human model of rapidly progressive disease in which the effect of antithrombotic treatment on the progress of arterial atheroma will be assessed (Dublin). A number of possible ways of inhibiting thrombosis will be tested; we anticipate the possibility to test within the Westerr European Centres, SHT2 antagonism, aspirin and thromboxane system inhibition, and thrombin inhibition. The participation of the Eastern European centres will permit us to undertake a much more comprehensive study of platelet function and its changes in CAD. The relationship of such platelet function studies to the information coming from the laboratories in London, Rotterdam and Dublin, will be of paticular importance. We are particularly keen to study platelets from those patients in whom the presence of thrombus has been identified by coronary angiography (e.g.Kobzar Tallinn, Estonia). The interaction of platelets with the vessel wall and their effects on blood rheology (Mircioiu, Bucharest) is another additional aspect not covered by the original group; this should include the field of microparticle separation (Zakharov, Novosibirsk). These studies are also relevant to our objective to explore antithrombotic (including antiplatelet) therapies as a means of controlling CAD. Non-platelet antithrombotic therapeutic possibilities include chromium bioactive compounds which early studies suggest may mobilize cholester plaques (Beran, Prague). Patients for especial targeting in these therapeutic efforts are those identified by electrical mapping (Czerwinska, Warsawa). Program(-y) IC-PECO/COPERNICUS - Scientific and technological cooperation between the European Community and European non-member countries, 1992- Temat(-y) 0201 - CEEC participation in BIOMEDICAL AND HEALTH RESEARCH programme Zaproszenie do składania wniosków Data not available System finansowania CSC - Cost-sharing contracts Koordynator IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE Wkład UE Brak danych Adres South Kensington Campus LONDON Zjednoczone Królestwo Zobacz na mapie Koszt całkowity Brak danych Uczestnicy (1) Sortuj alfabetycznie Sortuj według wkładu UE Rozwiń wszystko Zwiń wszystko Institute of Chemistry - Estonian Academy of Sciences Estonia Wkład UE Brak danych Adres 15,Akadeemia Tee 0026 Tallinn Zobacz na mapie Koszt całkowity Brak danych
